博瑞醫藥(688166.SH)簽訂2個項目投資協議 總投資約13億元
格隆匯11月13日丨博瑞醫藥(688166.SH)公佈,為進一步做強做大公司主業,擴大原料藥產能,加快推進原料藥製劑前向一體化進程,實現產業升級,公司全資子公司博瑞泰興擬與江蘇省泰興經濟開發區管理委員會簽署《博瑞生物醫藥泰興市有限公司原料藥項目投資協議書》及《博瑞生物醫藥泰興市有限公司高端製劑項目投資協議書》,上述兩個投資項目,其中原料藥項目佔地158畝,項目總投資約為8億元人民幣;高端製劑項目佔地100畝,項目總投資約為5億元人民幣。
原料藥項目竣工後三年最低畝均銷售達500萬元/畝?年、最低畝均税收達40萬元/畝(不含代徵綠地面積)。高端製劑項目竣工後三年最低畝均銷售達400萬元/畝?年、最低畝均税收達35萬元/畝(不含代徵綠地面積)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.